Wearable Health Solutions, Inc. (WHSI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.8 Million USD | 56.31% |
| 2022 | 2.43 Million USD | -42.9% |
| 2021 | 4.25 Million USD | 44.95% |
| 2020 | 2.93 Million USD | 55.11% |
| 2019 | 1.89 Million USD | 8.27% |
| 2018 | 1.74 Million USD | 5.65% |
| 2017 | 1.65 Million USD | -2.03% |
| 2016 | 1.69 Million USD | 56.01% |
| 2015 | 1.08 Million USD | -66.18% |
| 2014 | 3.2 Million USD | -51.45% |
| 2013 | 6.59 Million USD | 40.26% |
| 2012 | 4.7 Million USD | 38.21% |
| 2011 | 3.4 Million USD | -22.76% |
| 2010 | 4.4 Million USD | 50.71% |
| 2009 | 2.92 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.56 Million USD | -6.12% |
| 2024 Q2 | 3.18 Million USD | -10.8% |
| 2023 FY | 3.8 Million USD | 56.31% |
| 2023 Q1 | 2.46 Million USD | 1.18% |
| 2023 Q4 | 3.8 Million USD | 25.49% |
| 2023 Q3 | 3.02 Million USD | 12.79% |
| 2023 Q2 | 2.68 Million USD | 9.14% |
| 2022 FY | 2.43 Million USD | -42.9% |
| 2022 Q1 | 3.95 Million USD | -7.16% |
| 2022 Q2 | 2.64 Million USD | -33.2% |
| 2022 Q3 | 2.48 Million USD | -5.88% |
| 2022 Q4 | 2.43 Million USD | -2.19% |
| 2021 Q3 | 3.98 Million USD | 0.0% |
| 2021 FY | 4.25 Million USD | 44.95% |
| 2021 Q4 | 4.25 Million USD | 6.94% |
| 2021 Q1 | 3.69 Million USD | 25.62% |
| 2020 Q3 | 2.91 Million USD | 15.59% |
| 2020 FY | 2.93 Million USD | 55.11% |
| 2020 Q1 | 2.33 Million USD | 23.36% |
| 2020 Q2 | 2.51 Million USD | 7.85% |
| 2020 Q4 | 2.93 Million USD | 0.86% |
| 2019 Q3 | 1.89 Million USD | 0.09% |
| 2019 FY | 1.89 Million USD | 8.27% |
| 2019 Q2 | 1.89 Million USD | 0.04% |
| 2019 Q1 | 1.88 Million USD | 8.03% |
| 2019 Q4 | 1.89 Million USD | 0.09% |
| 2018 Q1 | 1.86 Million USD | 12.58% |
| 2018 FY | 1.74 Million USD | 5.65% |
| 2018 Q4 | 1.74 Million USD | -0.43% |
| 2018 Q3 | 1.75 Million USD | -12.17% |
| 2018 Q2 | 2 Million USD | 7.31% |
| 2017 Q4 | 1.65 Million USD | -3.05% |
| 2017 Q3 | 1.7 Million USD | -5.39% |
| 2017 Q2 | 1.8 Million USD | 11.7% |
| 2017 Q1 | 1.61 Million USD | -4.38% |
| 2017 FY | 1.65 Million USD | -2.03% |
| 2016 Q4 | 1.69 Million USD | 15.86% |
| 2016 Q2 | 1.12 Million USD | -2.12% |
| 2016 Q1 | 1.14 Million USD | 5.89% |
| 2016 Q3 | 1.45 Million USD | 29.92% |
| 2016 FY | 1.69 Million USD | 56.01% |
| 2015 Q3 | 3.58 Million USD | 5.04% |
| 2015 Q4 | 1.08 Million USD | -69.8% |
| 2015 Q1 | 3.26 Million USD | 2.04% |
| 2015 FY | 1.08 Million USD | -66.18% |
| 2015 Q2 | 3.41 Million USD | 4.47% |
| 2014 Q3 | 3.25 Million USD | -2.72% |
| 2014 FY | 3.2 Million USD | -51.45% |
| 2014 Q4 | 3.2 Million USD | -1.57% |
| 2014 Q2 | 3.34 Million USD | -46.27% |
| 2014 Q1 | 6.22 Million USD | -5.61% |
| 2013 Q1 | 4 Million USD | -14.9% |
| 2013 Q2 | 7.24 Million USD | 81.04% |
| 2013 Q3 | 7.08 Million USD | -2.29% |
| 2013 Q4 | 6.59 Million USD | -6.83% |
| 2013 FY | 6.59 Million USD | 40.26% |
| 2012 Q2 | 6.42 Million USD | 35.73% |
| 2012 Q3 | 5 Million USD | -22.0% |
| 2012 Q4 | 4.7 Million USD | -6.11% |
| 2012 FY | 4.7 Million USD | 38.21% |
| 2012 Q1 | 4.73 Million USD | 39.03% |
| 2011 Q1 | 4.18 Million USD | -5.02% |
| 2011 Q2 | 3.57 Million USD | -14.49% |
| 2011 Q4 | 3.4 Million USD | -0.19% |
| 2011 FY | 3.4 Million USD | -22.76% |
| 2011 Q3 | 3.41 Million USD | -4.71% |
| 2010 Q2 | 22.81 Million USD | 492.82% |
| 2010 FY | 4.4 Million USD | 50.71% |
| 2010 Q4 | 4.4 Million USD | 2.88% |
| 2010 Q3 | 4.28 Million USD | -81.23% |
| 2010 Q1 | 3.84 Million USD | 31.63% |
| 2009 Q3 | 2.7 Million USD | 6.53% |
| 2009 Q4 | 2.92 Million USD | 8.13% |
| 2009 Q1 | 48.36 Thousand USD | 0.0% |
| 2009 Q2 | 2.53 Million USD | 5147.38% |
| 2009 FY | 2.92 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.34 Million USD | -61.725% |
| Ansell Limited | 1.32 Billion USD | 99.714% |
| Ansell Limited | 1.33 Billion USD | 99.715% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 126.33 Million USD | 96.992% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 943.17 Thousand USD | -302.926% |
| Psykey, Inc. | 2.47 Million USD | -53.608% |
| ConvaTec Group Plc | 2.01 Billion USD | 99.812% |
| ConvaTec Group Plc | 2.02 Billion USD | 99.812% |
| Encision Inc. | 1.98 Million USD | -91.55% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 3.04 Million USD | -24.99% |
| Innovative MedTech Inc. | 6.13 Million USD | 38.054% |
| LifePoint, Inc. | 2.45 Million USD | -54.85% |
| Medite Cancer Diagnostics, Inc. | 10.18 Million USD | 62.673% |
| Paradigm Medical Industries, Inc. | 3.4 Million USD | -11.773% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 3.04 Million USD | -24.996% |
| Reflect Scientific, Inc. | 776.32 Thousand USD | -389.52% |
| SmileDirectClub, Inc. | 982.26 Million USD | 99.613% |
| Sector 10, Inc. | 9.84 Million USD | 61.401% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.35 Billion USD | 99.72% |
| SheerVision, Inc. | 1.43 Million USD | -165.494% |
| United Health Products, Inc. | 1.99 Million USD | -90.122% |
| Vasamed, Inc. | 1 Million USD | -278.025% |
| Yubo International Biotech Limited | 2.91 Million USD | -30.418% |